Logo
x

Search

Subscribe Now

Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Reports the US FDA’s Approval of Imcivree (Setmelanotide) for Patients as Young as 2 Years Old

Rhythm Pharmaceuticals Reports the US FDA’s Approval of Imcivree (Setmelanotide) for Patients as Young as 2 Years Old

  • December 24, 2024
Rhythm Pharmaceuticals Launches Imcivree (setmelanotide) for Obesity and Control of Hunger in Bardet-Biedl Syndrome in Germany

Rhythm Pharmaceuticals Launches Imcivree (setmelanotide) for Obesity and Control of Hunger in Bardet-Biedl Syndrome in Germany

  • April 25, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.